MEN2312 / Menarini, Insilico Medicine - LARVOL DELTA

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=240 | Recruiting | Sponsor: Stemline Therapeutics, Inc. | Trial completion date: Oct 2026 ➔ Oct 2029 | Trial primary completion date: Jun 2026 ➔ Oct 2027

First-in-human • Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • AKT1 • CDK4 • PIK3CA • PTEN

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=124 | Recruiting | Sponsor: Stemline Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Monotherapy • Breast Cancer • Oncology • Solid Tumor

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=124 | Not yet recruiting | Sponsor: Stemline Therapeutics, Inc.

Metastases • Monotherapy • New P1 trial • Breast Cancer • Oncology • Solid Tumor

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=240 | Recruiting | Sponsor: Stemline Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Monotherapy • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • AKT1 • PIK3CA • PTEN

MEN2312-01: A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer (clinicaltrialsregister.eu) - P1 | N=46 | Not yet recruiting | Sponsor: Stemline Therapeutics Inc.

First-in-human • Monotherapy • New P1 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=240 | Recruiting | Sponsor: Stemline Therapeutics, Inc. | Trial primary completion date: Oct 2025 ➔ Jun 2026

First-in-human • Monotherapy • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • AKT1 • PIK3CA • PTEN

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=240 | Recruiting | Sponsor: Stemline Therapeutics, Inc. | N=124 ➔ 240

Enrollment change • First-in-human • Monotherapy • Breast Cancer • Oncology • Solid Tumor